Compare Godaddy Inc (GDDY) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Mesoblast Limited — how do they compare? Godaddy Inc trades at $90.75 (market cap $11.49B), while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: Godaddy Inc is far larger — about 5.2× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals.
| GDDY | MESO | |
|---|---|---|
Market Cap | $11.49B | $2.21B |
Sector | Technology | Technology |
52-Week High | $148.88 | $20.96 |
52-Week Low | $75.07 | $12.88 |
Enterprise Value | $14.18B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $91.81, up 0.34% today, with a bearish technical signal but strong earnings beats in recent quarters. The company shows robust fundamentals with a 17.83% net income margin and a P/E of 13.48, indicating potential undervaluation. However, recent news highlights multiple securities investigations, creating investor uncertainty. Revenue growth is steady, projected at $5.1B for 2026, while cash flow trends improved in 2024 before a slight dip in 2025.
The stock presents a mixed outlook: analyst consensus is bullish with a $112.13 price target (21 buys, 15 holds, 1 sell), but technical indicators and legal risks weigh on near-term sentiment. Key opportunities include consistent earnings outperformance and solid profitability, while risks involve ongoing legal probes and high debt levels. Investors should balance fundamental strength against headline volatility.
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
